cover image for summer 2025 New therapies, payer strategies and pipeline updates shaping the future of managed care  Prime Therapeutics /summer-2025-prime-therapeutics-report The Prime Therapeutics...

Configure the table properties Dosage and administration In the Phase 3 VALOR clinical trial, brepocitinib was administered orally once daily at a dose of 15 mg or 30 mg for 52 weeks. Place in...

Event features Caitlin Berry, senior principal of public policy and government affairs at Prime Therapeutics

Cover image for Summer 2024 Prime Therapeutics Report Pulmonary arterial hypertension: Exciting new approval and payer impact Prime Therapeutics /2024-summer-prime-therapeutics-report The Prime...